Prospects for immunotherapy of malignant disease

Clinical and Experimental Immunology

Volumn 131, Issue 1, 2003, Pages 1-7

  Morris, E C ^a   Bendle, G M ^a   Stauss, H J ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Adoptive transfer; Allo restricted CTL; Immunotherapy; TCR gene transfer; Vaccination

Indexed keywords

CANCER VACCINE; EPITOPE; GLYCOPROTEIN GP 100; HLA A1 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOCYTE DIFFERENTIATION ANTIGEN; MONOPHENOL MONOOXYGENASE; PROTEIN MDM2; RECOMBINANT GAMMA INTERFERON; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; BINDING AFFINITY; CANCER; CANCER INHIBITION; CELL; CELL SPECIFICITY; CELL TRANSFER; CELL TYPE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPSTEIN BARR VIRUS; GENE; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTECTION; QUALITY OF LIFE; REVIEW; T LYMPHOCYTE; TISSUE; TUMOR CELL; TUMOR REGRESSION; VACCINATION; VIRUS INFECTION;

ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CANCER VACCINES; FORECASTING; GENE THERAPY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; MODELS, ANIMAL; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; TUMOR ESCAPE; VACCINATION;

EID: 0037234633     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02055.x     Document Type: Review

References (89)

1. Van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-7.
2. Disis ML, Gooley TA, Rinn K et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002; 20:2624-32.
3. Dredge K, Marriott JB, Todryk SM et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002; 168:4914-9.
4. Geiger JD, Hutchinson RJ, Hohenkirk LF et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61:8513-9.
5. Schnurr M, Galambos P, Scholz C et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: An in vitro model for the assessment of tumor vaccines. Cancer Res 2001; 61:6445-50.
6. + T cells in vivo. Proc Natl Acad Sci USA 1994; 91:3077-81.
7. Ponsaerts P, Van Den Bosch G, Cools N et al. Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J Immunol 2002; 169:1669-75.
8. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60:1028-34.
9. Hurwitz AA, Yu TFY, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 1998; 95:10067-71.
10. Offringa R, Van der Burg SH, Ossendorp F, Toes RE, Melief CJ. Design and evaluation of antigen-specific vaccination strategies against cancer. Curr Opin Immunol 2000; 12:576-82.
11. Rosenberg S. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380-4.
12. Jager E, Jager D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol 2002; 14:178-82.
13. Soares MM, Mehta V, Finn OJ. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 2001; 166:6555-63.
14. Mathiassen S, Lauemoller SL, Ruhwald M, Claesson MH, Buus S. Tumor-associated antigens identified by mRNA expression profiling induce protective anti-tumor immunity. Eur J Immunol 2001; 31:1239-46.
15. Xiang R, Primus FJ, Ruehlmann JM et al. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol 2001; 167:4560-5.
16. Bronte V, Apolloni E, Ronca R et al. Genetic vaccination with 'self' tryosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 2000; 60:253-8.
17. Mullins DW, Bullock TNJ, Collela TA, Robila VV, Engelhard VH. Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice. J Immunol 2001; 167:4853-60.
18. Magarian-Blander J, Ciborowski P, Hsia S, Watkins SC, Finn OJ. Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1. J Immunol 1998; 160:311-20.
19. + T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model. J Immunol 1998; 161:5133-7.
20. Cordaro TA, de Visser KE, Tirion FH, Schumacher TNM, Kruisbeek AM. Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J Immunol 2002; 168:651-60.
21. Zimmermann C, Prevost-Blondel A, Blaser C, Pircher H. Kinetics of the response of naive and memory CD8 T cells to antigen: Similarities and differences. Eur J Immunol 1999; 29:284-90.
22. + T cells to antigen stimulation in vivo. Nat Immunol 2000; 1:47-53.
23. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000; 191:1699-708.
24. Cheng WF, Hung CF, Chai CY et al. Tumor-specific immunity and anti-angiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001; 108:669-78.
25. Merad M, Sugie T, Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 2002; 99:1676-82.
26. Derby MA, Alexander-Miller MA, Tse R, Berzofsky JA. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol 2001; 166:1690-7.
27. Zeh HJ III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTL for two self-antigens demonstrate superior in vitro and in vivo antitumour efficacy. J Immunol 1999; 162:989-94.
28. Jager E, Ringhoffer M, Altmannsberger M et al. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997; 71:142-7.
29. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001; 107:477-84.
30. + melanoma patients mature monocyte-derived dendritic cells. J Immunol 2000; 165:3492-6.
31. 2-microglobulin mRNA in human colon carcinoma. J Exp Med 1989; 169:309-14.
32. Cromme FV, Airey J, Heemels MT et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179:335-40.
33. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-7.
34. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328-32.
35. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 1999; 163:1690-5.
36. Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001; 98:8809-14.
37. Marchand M, van Baren N, Weynants P et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80:219-30.
38. Jager E, Maeurer M, Hohn H et al. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer 2000; 86:538-47.
39. Coulie PG, Karanikas V, Colau D et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 2001; 98:10290-5.
40. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190:1669-78.
41. Matzinger P, Zamoyska R, Waldmann H. Self tolerance is H-2-restricted. Nature 1984; 308:738-41.
42. Lo D, Burkly LC, Widera G et al. Diabetes and tolerance in transgenic mice expressing class II MHC molecules in pancreatic B cells. Cell 1988; 53:159-68.
43. Ohashi PS, Oehen S, Buerki K et al. Ablation of 'tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991; 65:305-17.
44. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987; 165:302-19.
45. Schonrich G, Kalinke U, Momburg F et al. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 1991; 65:293-304.
46. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:314-7.
47. Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2 regulated FAS-mediated T cell apoptosis. Immunity 1998; 8:615-23.
48. Singer GG, Abbas AK. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994; 1:365-71.
49. Walker L, Abbas AK. The enemy within: Keeping self reactive T cells at bay in the periphery. Nature Rev Immunol 2002; 2:11-9.
50. Collela TA, Bullock TNJ, Russell LB et al. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy. J Exp Med 2000; 191:1221-31.
51. + T cells. Eur J Immunol 1992; 22:1013-22.
52. + T cell-mediated spontaneous diabetes in neonatal mice. Proc Natl Acad Sci USA 1999; 96:3854-8.
53. + T cell tolerance to peripherally expressed antigens. J Immunol 1999; 163:723-7.
54. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cells clones. Science 1992; 257:238-41.
55. Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lympho-proliferation. Lancet 1995; 345:9-13.
56. Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Blood 1998; 92:1549-55.
57. Gustafsson A, Levitsky V, Zou JZ et al. Epstein-Barr virus (EBV) laod in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95:807-14.
58. Khanna R, Bell S, Sherritt M et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999; 96:10391-6.
59. Haque T, Haque T, Amlot PL et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol 1998; 160:6204-9.
60. Barnes DWH, Corp MJ, Loutit JF, Neal FE. Treatment of murine leukaemia with x-rays and homologous bone marrow. Preliminary communication. Br Med J 1956; 2:626-7.
61. Weiden PL, Fluornoy N, Thomas ED et al. Antileukaemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1979; 300:1068-73.
62. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED and the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304:1529-33.
63. Maraninchi D, Gluckman E, Blaise D et al. Impact of T cell depletion on outcome of allogeneic bone-marrow transplantation for standard risk leukaemias. Lancet 1987; 2:175-8.
64. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients. Blood 1990; 76:2462-5.
65. Porter DL, Roth MS, McGarigle C, Ferrara J, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330:100-6.
66. Dazzi F, Szydlo RM, Cross NCP et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96:2712-6.
67. Guglielmi C, Arcese W, Dazzi F et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: Prognostic relevance of the initial cell dose. Blood 2002; 100:397-405.
68. Mackinnon S, Papadopolous EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86:1261-8.
69. Mackinnon S. Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation? Br J Haematol 2000; 110:12-7.
70. Peggs KS, Mackinnon S. Cellular therapy: Donor lymphocyte infusion. Curr Opin Hematol 2001; 8:349-54.
71. Ringden O, Hermans J, Labopin M, Apperley J, Gorin NC, Gratwohl A. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Leuk Lymph 1996; 24:71-9.
72. Zikos P, Van Lint MT, Lamparelli T et al. Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: Favorable impact of chronic graft-versus-host disease on survival and relapse. Haematologica 1998; 83:896-903.
73. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334:281-5.
74. Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 1999; 5:839-42.
75. Dickinson AM, Wang XN, Sviland L et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002; 8:410-4.
76. Mutis T, Blokland E, Kester M, Schrama E, Goulmy E. Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: A potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation. Blood 2002; 100:547-52.
77. Warren EH, Gavin M, Greenberg PD, Riddell SR. Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Curr Opin Hematol 1998; 5:429-33.
78. + T cells: A common basis between tumor immunity and autoimmunity. J Immunol 1999; 163:5211-8.
79. Woo EY, Yeh H, Chu CS et al. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168:4272-6.
80. Rammensee HG, Bevan MJ. Evidence from in vitro studies that tolerance to self antigens is MHC-restricted. Nature 1984; 308: 741-4.
81. Sadovnikova E, Stauss H. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: Reagents for tumor immunotherapy. Proc Natl Acad Sci USA 1996; 93:13114-8.
82. Sadovnikova E, Jopling L, Soo KS, Stauss HJ. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol 1998; 28:193-200.
83. + progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95:2198-203.
84. Bellantuono I, Gao L, Parry S et al. Two distinct HLA-A0201-presented epitopes of the Wilm's tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 2002; 100:36835-7.
85. Stanislawski T, Voss R-H, Lotz C et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001; 2:962-70.
86. Kessels HW, van Den Boom MD, Spits H, Hooijberg E, Schumacher TN. Changing T cell specificity by retroviral T cell receptor display. Proc Natl Acad Sci USA 2000; 97:14578-83.
87. Kessells HW, de Visser KE, Kruisbeek AM, Schumacher TNM. Circumventing T-cell tolerance to tumour antigens. Biologicals 2001; 29:277-83.
88. Chames P, Willemsen RA, Rojas G et al. TCR-like human antibodies expressed on human CTL mediate antibody affinity-dependent cytolytic activity. J Immunol 2002; 169:1110-8.
89. Yang L, Qin X-F, Baltimore D, Van Parijs L. Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells. Proc Natl Acad Sci USA 2002; 99:6204-9.